CanSino Biologics Inc
06185
Company Profile
Business description
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Contact
185 South Avenue
401-420, 4th Floor, Biomedical Park
TEDA West District
Tianjin
CHNT: +86 4009222099
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,105
Stocks News & Analysis
stocks
Procter & Gamble earnings: Frigid sales and margins don’t suggest cracks in its standing
North America was a notable blemish, down 2% on an organic basis.
stocks
Our view on Santos after production is ramped up
Barossa at 75% capacity and Pikka undergoing commissioning.
stocks
GE Aerospace earnings: No good deed goes unpunished
We’ve raised our fair value estimate of GE Aerospace stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.90 | 15.70 | 0.17% |
| CAC 40 | 8,143.05 | 5.84 | -0.07% |
| DAX 40 | 24,900.71 | 44.24 | 0.18% |
| Dow JONES (US) | 49,086.14 | 297.87 | -0.60% |
| FTSE 100 | 10,143.44 | 6.61 | -0.07% |
| HKSE | 26,749.51 | 119.55 | 0.45% |
| NASDAQ | 23,509.22 | 73.20 | 0.31% |
| Nikkei 225 | 53,846.87 | 157.98 | 0.29% |
| NZX 50 Index | 13,448.24 | 108.63 | -0.80% |
| S&P 500 | 6,915.87 | 2.52 | 0.04% |
| S&P/ASX 200 | 8,860.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,136.16 | 13.59 | 0.33% |